Concourse Financial Group Securities’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-390
Closed -$8.18K 845
2024
Q4
$8.18K Buy
390
+2
+0.5% +$44 ﹤0.01% 1766
2024
Q3
$9.46K Sell
388
-116
-23% -$3.1K ﹤0.01% 1704
2024
Q2
$12.7K Buy
504
+53
+12% +$1.5K ﹤0.01% 1630
2024
Q1
$13.5K Sell
451
-40
-8% -$1.18K ﹤0.01% 1620
2023
Q4
$15.6K Sell
491
-78
-14% -$2.45K ﹤0.01% 1553
2023
Q3
$20.1K Buy
569
+462
+432% +$17.6K ﹤0.01% 1437
2023
Q2
$4.07K Buy
107
+21
+24% +$837 ﹤0.01% 1880
2023
Q1
$3.25K Sell
86
-24
-22% -$923 ﹤0.01% 1966
2022
Q4
$4.66K Hold
110
﹤0.01% 1875
2022
Q3
$4K Sell
110
-35
-24% -$1.23K ﹤0.01% 1677
2022
Q2
$5K Buy
145
+86
+146% +$2.79K ﹤0.01% 1837
2022
Q1
$2K Hold
59
﹤0.01% 2017
2021
Q4
$2K Buy
59
+21
+55% +$876 ﹤0.01% 2197
2021
Q3
$2K Hold
38
﹤0.01% 2217
2021
Q2
$2K Hold
38
﹤0.01% 2184
2021
Q1
$1K Hold
38
﹤0.01% 2238
2020
Q4
$2K Sell
38
-52
-58% -$1.94K ﹤0.01% 2091
2020
Q3
$3K Buy
90
+18
+25% +$651 ﹤0.01% 1939
2020
Q2
$2K Sell
72
-17
-19% -$463 ﹤0.01% 1900
2020
Q1
$2K Sell
89
-195
-69% -$4.35K ﹤0.01% 1886
2019
Q4
$6K Hold
284
﹤0.01% 1572
2019
Q3
$6K Buy
+284
New +$5.59K ﹤0.01% 1267

Other funds holding GMAB

Concourse Financial Group Securities's GMAB Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Genmab (GMAB) in Q1 2025, closing a stake of 390 shares — an estimated $8.18K sold.

Concourse Financial Group Securities first reported a position in GMAB in Q3 2019 and held it in 22 quarters. The position peaked at $20.1K in Q3 2023. 220 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 390 Genmab shares in Q1 2025, an estimated $8.18K.
  • Concourse Financial Group Securities first reported a position in Genmab in Q3 2019 and held it in 22 quarters.
  • Concourse Financial Group Securities's Genmab position peaked at $20.1K in Q3 2023.
  • 220 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.